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INTRODUCTION 
Middle East Respiratory Syndrome 
(MERS) is a respiratory infection caused by 
MERS-Coronavirus (MERS-CoV) and is 
known to be new to humans.
1
 The infection 
was at first assigned HCoV-EMC2 however 
after worldwide agreement it was renamed to 
MERS-CoV.
2
 MERS-CoV is genetically 
linked to obtained sequence from bats 
originated from Europe, Africa, Asia and 
Middle East.
3
 The most common symptoms of 
MERS are shortness of breath (48%), cough 
(87%), fever (87%) and gastrointestinal 
symptoms (35%) and patients develop acute 
respiratory illness.
4
 Studies performed on 
cases identified in family clusters in Saudi 
Arabia hospitals.
4-6
 and some European 
countries.
7,8
 also demonstrate that every 
person with MERS-CoV can show different 
respiratory and non-respiratory symptoms. 
This disease was first reported by health 
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ABSTRACT 
Background and aims: Middle East respiratory syndrome (MERS) is a viral respiratory 
illness caused by a coronavirus. After the primary onset of MERS in Saudi Arabia, in 
September 2015 cases began to increase. The number of laboratory-affirmed cases by 
MERS-CoV in the Middle East has been being increased recently. 
Methods: In this current review article, by using the terms “MERS” and “coronavirus” 
we first searched for English language articles in the PubMed database, published in last 
five years. Then by a detailed review of related articles, we provided a comprehensive 
information about epidemiology, genetic, host and coronavirus treatment. 
Results: More importantly, evidences of human-to-human transmission in Europe and 
America indicate that the viral adaptations in humans may precede a large-scale epidemic. 
The genome of Coronaviruses is a linear positive-sense single stranded large RNA and they 
are enveloped viruses that have a helical symmetric nucleocapsid. Some new insights have 
been provided in previous few months in to the animal Coronavirus hosts, transmissibility, 
contagion of MERS Co-V and ideal laboratory diagnostic methods. 
Conclusion: It seems crucial to control this new human infection “MERS-CoV” by 
collaborating global and local health authorities and their continual support for further 
research on it. 
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officials in the eastern province of Saudi 
Arabia in September 2012.
9
 After a short time 
a patient with acute respiratory illness caused 
by the same virus was identified in London.
7
 
There was an outbreak of MERS infection in 
April 2014 in Saudi Arabia where 688 
individuals has been infected and 282 MERS 
related deaths have been reported.
10
 Shortly 
thereafter, some new cases were identified in 
United States, South Korea, Philippines and 
United Kingdom. The WHO reported 1227 
laboratory confirmed MERS cases and 
449(39%) MERS related deaths from 
September 2012 to 10 March 2015.
11
 It is 
worthy to note that the worldwide health and 
economy have been affected by outbreak of 
MERS. In addition, the global health and 
economical outcomes of MERS prevalence 
may be decreased by employing anticipating 
approaches.
12
 
After the primary onset of MERS in 
Saudi Arabia, in September 2015 cases began 
to increase due to hajj pilgrimage.
13
 While a 
total number of 1029 infected cases and 452 
MERS related deaths have been reported in 
Saudi Arabia,
14
 there were only two diagnosed 
cases in United States with no death. The first 
case diagnosed for MERS in the U.S was 
confirmed on May 2, 2014 by Center of 
Disease Control and Prevention (CDC) in a 
man who had been in Saudi Arabia one week 
earlier. The second patient was identified on 
May 12, 2014 in Florida.
15,16
 
After a short time in May 14, 2014 the 
first case was reported in Netherlands. The 
first case in South Korea was identified in 
May 2015. A number of 19 individuals in 
South Korea had MERS and 184 cases 
reported with infection.
17
 Another report 
indicated the infection of 74 persons with 10 
MERS related death in United Arab 
Emirates.
18
 A total of 19 infected cases and 6 
related death was also reported in March 12, 
2015 in Jordan.
19
 After Jordan, officials of 
Qatar reported 10 CoV infected individuals 
with 40% fatality in March 2015.
20
 Iran 
ranked in 7th position in WHO's report 
because of 5 infected person and 2 death.
21
 
Other countries like United Kingdom, 
Germany, Kuwait, etc. reported less than 5 
infected cases. Because of MERS 
transmission by infected person's respiratory 
secretions, it is not surprising that its 
prevalence is much higher in neighboring area 
in Middle East than other regions.
22
 
The genome of Coronaviruses is a 
linear positive-sense single stranded large 
RNA and they are enveloped viruses that 
have a helical symmetric nucleocapsid. The 
Coronaviruses genomic size is about 26 to 
32 kilobases which encodes both structural 
and non-structural proteins including one 
structural nucleocapsid protein and one  
non-structural protein (NSP2) responsible for 
the viral RNA synthesis.
23
 There is a 
methylated nucleotide cap in 5'-end of its 
genome and the 3'-end has a poly A sequence. 
Six various strains of Coronaviruses are 
currently known to infect humans, however, 
the molecular clock analyses have not been 
able to identify MERC-CoV ancestors.
24
 
Coronavirus uses full-length minus–strand 
process for genome replication. Transcription 
of this virus is really complicated and begins 
with interruptive extension of mRNAs that 
contains 5' and 3' end sequences.
25
 
Coronavirus Genomic RNA encodes for 
ORF1a and ORF1b, after translation by 
ribosomal frame shifting proteins pp1a and 
pp1ab are processed into the viral 
polymerase (RdRp) and other non-structural 
proteins involved in RNA synthesis. 
Structural proteins are expressed as 
subgenomic RNAs. Each RNA (genomic 
and subgenomic) is translated to yield only 
the protein encoded by the 5’-ORF.26 
These types of viruses were first extracted 
from chicken in 1973. In addition to human, 
this virus can infect birds, cats, dogs, pigs and 
rodents. Dipeptidyl peptitase 4 (DPP4, CD26) 
has been identified as a cellular receptor for 
MERS-CoV.
27
 The kidney and lung pathology 
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of infection is consistent with distribution of 
this receptor in mammalian tissues.
27
 Upper 
respiratory and gastrointestinal tract of 
mammals and birds are the first targets of 
infection.
28
 Epithelial cells are most common 
target for Coronaviruses but they also can 
target macrophages and other distributed cells. 
Coronavirus uses endocytosis mediated 
methods in host cells after attachment to the S 
protein of host receptors. After fusion of virus 
membrane with endosomal membrane 
mediated by S2 protein, the RNA genome of 
virus is released into cytoplasm. After 
replication and transcription of structural and 
non-structural proteins new virions release by 
exocytosis.
29
 
Nowadays, no specific therapy or vaccine 
has been identified for Corona-Virus related 
infections.
30
 However the factors that were 
used during SARS epidemic of 2003, might 
be useful against the related MERS 
coronavirus. The clinical experience from 
SARS proposes that various mediations 
including broad spectrum antiviral ribavirin 
with and without corticosteroids, interferon 
alfa with corticosteroids, ribavirin with 
lopinavir and ritonavir, and convalescent 
plasma may improve the outcome in patients. 
In most viral infections, the timing of the start 
of antiviral factors is serious.
31
 One of the 
recent studies compared oseltamivir effect 
against ribavirin and reported no significant 
response to ribavirin, however, the treatment 
were started after 10-14 days of side effects 
which may have prompted to the poorer 
outcomes.
32
 According to a number of studies, 
it seems that the use of ribivin in appropriate 
time, may improve the outcome and decrease 
MERS related mortality.
33
 
 
CONCLUSION 
The appearance of MERS-CoV 
highlighted the importance of Coronaviridae 
family as human pathogens. Two highly 
pathogenic Coronaviruses have been 
identified in china; SARS-CoV (2003) and 
MERS-Cov (2012), both widely spread and 
caused considerable negative outcomes to 
global health and economy. 
After WHO's declaration about emerging 
MERS-CoV and the first two cases of MERS-
CoV infection on September 23, 2012, all of 
the clinicians and researchers have cooperated 
for prevention a SARS-like epidemic. 
Unravelling of genomic characteristics of 
MERS-CoV including its genome structure, 
phylogenetic associations with other 
coronaviruses, tissue and species tendency, 
and target receptor, has upgraded our 
comprehension of the clinical exposure, 
pathogenesis, epidemiology, transmission and 
planning a diagnostic and therapeutic methods 
of this novel human coronavirus. 
Nevertheless, concerning questions about 
animal hosting potency of the virus, 
evolutionary process, transmission, and the 
prognostic variables and therapeutic methods 
of the infection, remain unclear. So it seems 
crucial to control this new human infection 
“MERS-CoV” by collaborating global and 
local health authorities and their continual 
support for further research on it. 
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